BLUE’s action goes up: analysis suggests that gene therapy was not to blame for cancer
Bluebird Bio (BLUE) said on Wednesday that his experimental gene therapy for blood disorders was probably not to blame for a patient’s cancer diagnosis, causing BLUE’s action to burst. …
